2024.

• Nov.18.2024 R & D

  Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

• Oct.31.2024 Management / Finance

  Revisions of Consolidated Financial Forecasts and Introduction of Core Basis in Financial Results

• Oct.31.2024 Management / Finance

  Announcement on Financial Results for FY2024 Q2

• Oct.15.2024 Corporate

  Notice on the Recipients of the “Osamu Hayaishi Memorial Scholarship for Study Abroad” of the FY2025 Japanese Biochemical Society

• Oct.10.2024 Licensing

  Ono Enters into License Agreement for LCB97, an Antibody-Drug Conjugate, and Research Collaboration and License Agreement to generate novel ADC candidates by leveraging ConjuAll™ ADC platform with LigaChem Biosciences

• Oct.10.2024 R & D

  Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

• Oct.07.2024 R & D

  U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

• Sep.18.2024 R & D

  Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma

• Sep.12.2024 R & D

  Ono and Bristol-Myers Squibb KK Submit Supplemental Application of Opdivo and Yervoy in Combination Treatment in Japan to Expand the Use for Unresectable Advanced or Recurrent Microsatellite Instability-High Colorectal Cancer

• Aug.23.2024 R & D

  Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

• Aug.20.2024 Sustainability

  Ono Selected for ESG Investment Indexes Adopted by GPIF

• Aug.16.2024 R & D

  U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

• Aug.09.2024 R & D

  Ono and Bristol-Myers Squibb KK Submit Supplemental Application of Opdivo and Yervoy in Combination Treatment in Japan to Expand the Use for Unresectable Hepatocellular Carcinoma

• Aug.08.2024 Sustainability

  Ono Supports TNFD Recommendations and Discloses Information Aligned with TNFD Framework

• Aug.01.2024 Licensing

  Ono Enters into a New Option and Research Collaboration Agreement with Monash University to Discover and Create New Anti-GPCR Antibodies in the Autoimmune and Inflammatory Diseases

• Jul.31.2024 Management / Finance

  Announcement on Financial Results for FY2024 1Q

• Jul.22.2024 R & D

  Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

• Jul.19.2024 R & D

  European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

• Jul.18.2024 R & D

  Opdivo® Intravenous Infusion Approved in South Korea in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Patients with Unresectable or Metastatic Urothelial Carcinoma

• Jul.12.2024 Management / Finance

  Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation

• Jun.25.2024 R & D

  European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

• Jun.20.2024 Management / Finance

  Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation

• Jun.11.2024 Corporate

  Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

• Jun.05.2024 R & D

  Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial

• Jun.04.2024 R & D

  Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Earlier and Advanced Stages of Non-Small Cell Lung Cancer

• Jun.04.2024 R & D

  Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

• May.23.2024 R & D

  Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

• May.17.2024 R & D

  Ono Receives Approvals of BRAFTOVI® and MEKTOVI® for Expanded Use for Two New Indications in Japan

• May.13.2024 R & D

  Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

• May.09.2024 Management / Finance

  Announcement on Financial Results for FY2023

• May.09.2024 Management / Finance

  Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2024 and the Previous Fiscal Year

• May.08.2024 R & D

  European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

• May.07.2024 R & D

  U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

• May.07.2024 R & D

  CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

• Apr.30.2024 Corporate

  ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

• Apr.25.2024 Licensing

  Ono Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area

• Apr.10.2024 Corporate

  Support for Earthquake Relief Efforts in Eastern Taiwan

• Apr.05.2024 Corporate

  Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers

• Mar.29.2024 Management / Finance

  Ono Announces Completion of Cancellation of Treasury Stock

• Mar.27.2024 Corporate

  Ono Announces General Sponsorship for the “Theme Weeks” as Bronze Partner, at the Expo 2025 Osaka, Kansai, Japan

• Mar.22.2024 Licensing

  Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford

• Mar.21.2024 R & D

  ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

• Mar.21.2024 R & D

  Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma

• Mar.14.2024 Licensing

  Ono Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders

• Mar.12.2024 R & D

  U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

• Mar.11.2024 Sustainability

  Ono Selected as "2024 Health & Productivity Stock"

• Mar.11.2024 Licensing

  ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University

• Mar.06.2024 Licensing

  Ono Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101

• Mar.05.2024 Corporate

  ONO Receives Excellence Award at the Nikkei Integrated Report Award 2023

• Mar.04.2024 Management / Finance

  Ono Announces Status and Completion of Acquisition of Own Shares

• Mar.01.2024 Management / Finance

  Ono Announces Status of Acquisition of Own Shares

• Feb.21.2024 Licensing

  Ono Enters into a Drug Discovery Collaboration Agreement with EME Aiming at the Generation of Novel VHH Antibody Drugs

• Feb.19.2024 Licensing

  Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets

• Feb.14.2024 Licensing

  ONO Enters into an Option and Collaboration Agreement with Numab to Develop Multi-specific Antibody NM49

• Feb.13.2024 Licensing

  Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

• Feb.09.2024 R & D

  ONO Receives Supplemental Approval of Opdivo® in Japan for Expanded Use for Treatment of Unresectable Advanced or Recurrent Malignant Epithelial Tumors

• Feb.08.2024 R & D

  Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

• Feb.07.2024 Sustainability

  ONO Selected as Highest Rating A-List Company by CDP in Two Categories of “Climate Change” and “Water Security” in CDP 2023

• Feb.01.2024 Management / Finance

  Ono Announces Status of Acquisition of Own Shares

• Jan.31.2024 Management / Finance

  Announcement on Financial Results for FY2023 3Q

• Jan.29.2024 R & D

  Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial

• Jan.23.2024 R & D

  Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

• Jan.23.2024 R & D

  Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

• Jan.22.2024 R & D

  Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial

• Jan.11.2024 Corporate

  Notice of Changes in Representative Directors

• Jan.09.2024 Corporate

  Support for Disasters Caused by the 2024 Noto Peninsula Earthquake

• Jan.09.2024 R & D

  Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

• Jan.05.2024 Management / Finance

  Ono Announces Status of Acquisition of Own Shares